Puriblood Medical Co., Ltd. logo

Puriblood Medical Co., Ltd. (6847)

Market Closed
11 Aug, 05:30
TWSE TWSE
NT$
78. 30
-2.2
-2.7329%
NT$
1.31B Market Cap
- P/E Ratio
- Div Yield
31,157 Volume
- Eps
NT$ 80.5
Previous Close
Add Transaction
Day Range
77.3 80.2
Year Range
47.75 93.7
Want to track 6847 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6847 closed today lower at NT$78.3, a decrease of -2.7329% from yesterday's close, completing a monthly decrease of -3.0941% or -NT$2.5. Over the past 12 months, 6847 stock gained 15.6573%.
6847 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

6847 Chart

People also search for

Leader Electronics Inc.
NT$ 8.24
+0.6105%
Asia Neo Tech Industrial Co., Ltd.
NT$ 274.5
-6.1538%
Roundtop Machinery Industries Co. Ltd.
NT$ 19.65
-0.5063%
IROC Co., Ltd.
NT$ 164.5
+1.8576%
International Ocean Group
NT$ 27.9
-3.7931%

Puriblood Medical Co., Ltd. (6847) FAQ

What is the stock price today?

The current price is NT$78.30.

On which exchange is it traded?

Puriblood Medical Co., Ltd. is listed on TWSE.

What is its stock symbol?

The ticker symbol is 6847.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.31B.

Has Puriblood Medical Co., Ltd. ever had a stock split?

No, there has never been a stock split.

Puriblood Medical Co., Ltd. Profile

Professional Services Industry
Industrials Sector
- CEO
TWSE Exchange
TW0006847007 ISIN
Taiwan Country
42 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Puriblood Medical Co., Ltd. is a Taiwan-based company focused on developing and commercializing advanced blood cell separation products. Since its inception in 2016, Puriblood has dedicated itself to providing innovative solutions aimed at enhancing the safety and efficiency of blood transfusions and related medical procedures. Located in Hsinchu, Taiwan, the company leverages cutting-edge research and development to create products that meet the critical needs of healthcare providers and patients alike. Central to their innovation is the development of P-Tex Technology, a novel approach to blood filtration that uses a zwitterionic copolymer structure inspired by biological mechanisms.

Products and Services

  • Leukocyte Reduction Filters:

    Puriblood offers a range of leukocyte reduction filters designed for red blood cells, platelets, and whole blood. These products aim to improve patient outcomes by reducing the risk of non-hemolytic febrile transfusion reactions and other complications associated with leukocytes in transfused blood components.

  • Real-time Filtration Sets for Whole Blood:

    The company provides innovative filtration sets that enable real-time processing of whole blood. This allows for more efficient and immediate preparation of blood components for transfusion, potentially enhancing the quality of care for patients requiring blood transfusions.

  • Devin Blood Fractionation Membrane Filters:

    These specialized filters are designed for the efficient separation of blood components. Their use facilitates the precise extraction of specific blood elements, which is critical for various diagnostic and therapeutic applications.

  • Minipuri Cell Screening Syringe Filters:

    Targeted at laboratory and clinical settings, the Minipuri filters offer a convenient and effective solution for the rapid screening of cellular components in smaller volumes of blood or other biological fluids, enhancing the speed and accuracy of diagnostic processes.

  • P-Tex Technology:

    At the heart of Puriblood's innovation lies the P-Tex Technology, which is distinguished by its bio-inspired molecular formula – a zwitterionic copolymer structure. This technology forms the basis of their advanced filtration products, boasting high efficiency and selectivity in blood component separation while minimizing potential adverse reactions.

Contact Information

Address: No.11, Gongye East 9th Road
Phone: 886 3 668 7199